Sage Therapeutics (SAGE) Stock Price, News & Analysis

Company Overview

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $8.68 to $8.68
• 50-Day Range: $8.68 to $9.28
• 52-Week Range: $4.62 to $11.44
• Volume: N/A
• Average Volume: 3.63 million shs
• Market Capitalization: $543.54 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $7.85
• Consensus Rating: Reduce

Sage Therapeutics Stock Analysis - MarketRank™

Sage Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 845th out of 953 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.0 / 5
• Analyst Rating: Reduce

Consensus Rating

Sage Therapeutics has received a consensus rating of Reduce. The company's average rating score is 1.93, and is based on no buy ratings, 13 hold ratings, and 1 sell rating.

Downside Risk

Sage Therapeutics has a consensus price target of $7.85, representing about 9.6% downside from its current price of $8.68.

Amount of Analyst Coverage

Sage Therapeutics has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Sage Therapeutics are expected to grow in the coming year, from ($3.52) to ($2.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sage Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sage Therapeutics is -1.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Sage Therapeutics has a P/B Ratio of 1.47. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for SAGE.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Sage Therapeutics does not currently pay a dividend.

Dividend Growth

Sage Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.1 / 5
• Environmental Score: -1.60

Short Interest

There is no current short interest data available for SAGE.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sage Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.50% of the stock of Sage Therapeutics is held by insiders.

Percentage Held by Institutions

99.22% of the stock of Sage Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

SAGE Stock Analysis - Frequently Asked Questions

How were Sage Therapeutics' earnings last quarter?

Sage Therapeutics, Inc. (NASDAQ:SAGE) announced its quarterly earnings results on Wednesday, July, 30th. The biopharmaceutical company reported ($0.79) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $0.17. The business's revenue for the quarter was up 266.0% on a year-over-year basis.

Who are Sage Therapeutics' major shareholders?

Top institutional investors of Sage Therapeutics include Balyasny Asset Management L.P. (2.42%), Geode Capital Management LLC (2.17%), Alpine Associates Management Inc. (2.03%) and 683 Capital Management LLC (1.84%).
View institutional ownership trends.

What other stocks do shareholders of Sage Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Sage Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Visa (V).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 9/13/2025
• Next Earnings (Estimated): 11/04/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:SAGE
• CIK: 1597553
• Web: www.sagerx.com
• Phone: (617) 299-8380
• Fax: 617-299-8379
• Employees: 690
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Sage Therapeutics: $7.85
• High Price Target: $12.00
• Low Price Target: $4.00
• Potential Upside/Downside: -9.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.93
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($4.89)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$400.67 million
• Net Margins: -427.78%
• Pretax Margin: -427.78%
• Return on Equity: -67.10%
• Return on Assets: -58.42%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.16
• Quick Ratio: 9.13

Sales & Book Value

• Annual Sales: $41.24 million
• Price / Sales: 13.18
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.89 per share
• Price / Book: 1.47

Miscellaneous

• Outstanding Shares: 62,620,000
• Free Float: 59,177,000
• Market Cap: $543.54 million
• Optionable: Optionable
• Beta: 0.26